22 May 2013
Keywords: ilex, halts, trial, bladder, cancer, drug, firm
Article | 26 January 2004
US firm ILEX Oncology has discontinued a Phase III placebo-controlled trial of its eflornithine (DFMO) in patients with superficial bladder
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
21 May 2013
© 2013 thepharmaletter.com